Target Price | $65.56 |
Price | $12.20 |
Potential |
437.34%
register free of charge
|
Number of Estimates | 9 |
9 Analysts have issued a price target Arcturus Therapeutics Ltd 2026 .
The average Arcturus Therapeutics Ltd target price is $65.56.
This is
437.34%
register free of charge
$140.00
1,047.54%
register free of charge
$44.00
260.66%
register free of charge
|
|
A rating was issued by 11 analysts: 11 Analysts recommend Arcturus Therapeutics Ltd to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Arcturus Therapeutics Ltd stock has an average upside potential 2026 of
437.34%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 152.31 | 92.55 |
8.69% | 39.24% | |
EBITDA Margin | -60.49% | -138.82% |
34.08% | 129.50% | |
Net Margin | -53.14% | -86.74% |
198.15% | 63.22% |
11 Analysts have issued a sales forecast Arcturus Therapeutics Ltd 2025 . The average Arcturus Therapeutics Ltd sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Arcturus Therapeutics Ltd EBITDA forecast 2025. The average Arcturus Therapeutics Ltd EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Arcturus Therapeutics Ltd Analysts have issued a net profit forecast 2025. The average Arcturus Therapeutics Ltd net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.00 | -2.96 |
167.86% | 1.33% | |
P/E | negative | |
EV/Sales | 1.39 |
3 Analysts have issued a Arcturus Therapeutics Ltd forecast for earnings per share. The average Arcturus Therapeutics Ltd EPS is
This results in the following potential growth metrics and future valuations:
Arcturus Therapeutics Ltd...
Analyst | Rating | Action | Date |
---|---|---|---|
Wells Fargo |
Locked
➜
Locked
|
Locked | May 14 2025 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | May 13 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 10 2025 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
Wells Fargo |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
Analyst Rating | Date |
---|---|
Locked
Wells Fargo:
Locked
➜
Locked
|
May 14 2025 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
May 13 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 10 2025 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Mar 10 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Mar 07 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 07 2025 |
Locked
Wells Fargo:
Locked
➜
Locked
|
Mar 07 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.